RELEReleases

Biotech Results Diverge as Bladder Cancer Trial Succeeds, FDA Rejects Filing

A Phase 3 bladder cancer trial met its primary endpoint, while the FDA declined to approve a lung cancer drug application and a Phase 2 atopic dermatitis study missed its goals. The contrasting updates came as the S&P 500 and Nasdaq Composite fell on Monday, Nov. 16, 2026.

Bio & NewsNovember 17, 2026111 reads0

CG Oncology said its PIVOT-006 trial of investigational cretostimogene reduced recurrence risk by 68% versus the control arm in patients with intermediate-risk and high-grade Ta non-muscle invasive bladder cancer measuring 3 cm or less after complete tumor resection. The 367-patient study ran at about 90 sites in the United States and Canada. The company plans to submit a biologics license application in the second quarter of 2027 and present topline results on Dec. 2 at the Society of Urologic Oncology Annual Meeting. The hazard ratio was 0.32 (95% CI: 0.23, 0.45; p<0.0001).

Lexeo Therapeutics reported interim Phase I/II results for investigational gene therapy LX2020 in PKP2 arrhythmogenic cardiomyopathy. High-dose cohorts showed mean reductions of 80% in non-sustained ventricular tachycardia and 44% in premature ventricular contractions at the latest assessment. Ten participants had been dosed; nine had at least 12 months of follow-up by the Oct. 15, 2026, data cutoff. Lexeo said the FDA was open to guideline-defined non-sustained ventricular tachycardia as a primary surrogate endpoint for potential accelerated approval.

Summit Therapeutics said the FDA issued a complete response letter for its application for ivonescimab plus platinum-based chemotherapy in previously treated EGFR-mutated, locally advanced or metastatic non-squamous non-small cell lung cancer. The agency found substantial evidence of effectiveness had not been established without a statistically significant overall-survival improvement, according to Summit. In the Phase III HARMONi trial, the combination significantly improved progression-free survival (hazard ratio 0.52), while overall survival showed a positive but not statistically significant trend. Summit shares fell 16.5%, the Associated Press reported.

Aclaris Therapeutics said its Phase 2 ADMIRATION trial of investigational bosakitug did not meet primary or secondary endpoints in moderate-to-severe atopic dermatitis. The primary measure was percent change from baseline in Eczema Area and Severity Index score at week 24. The company reported target engagement, reductions in immune-activation biomarkers and general tolerability; it also said it had started a Phase 2b trial of modzatinib for moderate-to-severe lichen planus.

The broader market was lower: the S&P 500 fell 1.92% to 7,416.59 and the Nasdaq Composite dropped 2.49% to 24,509.76, according to CNBC's closing report. Research and Markets projects the global bladder cancer drugs market will expand from USD 6.89 billion in 2026 to USD 11.84 billion by 2032, a 9.41% compound annual growth rate.

Comments (0)

Leave a comment

No comments yet. Be the first!